Pfizer’s drop of a late-stage ADC this week may signal the ADC frenzy is cooling

University of Nottingham spinout is developing an antibody for peripheral artery disease that turns VEGF’s cancer paradigm on its head

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

Decade after first approval, bispecifics on the precipice of going mainstream

Newco, led by ex-Seagen CEO Epstein, announces $140M series A

BioNTech gearing up to advance BNT327 to Phase III for triple-negative breast cancer after promising Phase II survival data

Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more

PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting

BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more